The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review

被引:0
作者
Jonathan Adachi
Niall Lynch
Hans Middelhoven
Manjit Hunjan
Warren Cowell
机构
[1] McMaster University,Health Outcomes Research
[2] Global Health Outcomes,Healthcare Management
[3] Economic Value Strategy,undefined
[4] GlaxoSmithKline UK Ltd,undefined
[5] Roche Products Limited,undefined
来源
BMC Musculoskeletal Disorders | / 8卷
关键词
Vertebral Fracture; Fracture Risk; Alendronate; Osteoporotic Fracture; Risedronate;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 143 条
[1]  
Melton LJ(1997)Fractures attributable to osteoporosis; Report from the National Osteoporosis Foundation J Bone Miner Res 12 16-23
[2]  
Thamer R(2001)Clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis Endocrine Practice 7 293-312
[3]  
Ray NF(2001)Osteoporosis Prevention, Diagnosis, and Therapy JAMA 285 785-795
[4]  
Chan JK(2002)Meta-analysis of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for post menopausal osteoporosis Endocr Rev 23 570-578
[5]  
Chestnut CH(2004)Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Min Res 19 1241-1249
[6]  
Einhorn TA(2002)Long term persistence in use of statin therapy in elderly patients JAMA 288 455-461
[7]  
Johnston CC(1997)Assessing compliance to antihypertensive medication using computer-based pharmacy records Med Car 35 1164-1170
[8]  
Raisz LG(1997)Compliance with treatment regimens in chronic asymptomatic diseases Am J Med 102 43-49
[9]  
Silverman SL(2003)Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965-968
[10]  
Siris ES(2004)The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003-1008